Quantitation of Serum Free Light Chains

Bakker, A.; Bierma-Ram, Ageeth; Werf, Coby Elderman-van der; Strijdhaftig, Marcia L.; Zanden, Jelmer J. van

doi:10.1373/clinchem.2008.122416

Cited by 4 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The guidelines for monitoring disease states are based on the Freelite ® assays on the Siemens BNII system [17]. Numerical differences in the FLC ratio between the assays, partly due to the 'gap effect' in the Freelite ® assays and to differences in λFLC concentration between N Latex and Freelite ® assays mean that guideline response criteria based on Freelite ® assays may not fully apply to the N Latex FLC assays [10,17,[26][27][28][29][30][31][32][33]. However, N Latex FLC can accurately be used for prognostic stratification in AL amyloidosis patients based on the guidelines by Comenzo et al, as demonstrated by Mollee et al and Palladini et al [23,24,34].…”

Section: Assay Performance In Diseasementioning

confidence: 99%

Measurement of free light chains with assays based on monoclonal antibodies

Velthuis

Drayson

Campbell

2016

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Recently, serum free light chain (FLC) assays incorporating anti-kappa (κ) and anti-lambda (λ) FLC monoclonal antibodies have become available: N Latex FLC assay (Siemens) and Seralite® (Abingdon Health). The purpose of this review is to provide an overview of these two new monoclonal antibody-based methods. In doing so, the review will outline the performance characteristics of each method, including a summary of: assay principles, antibody specificity, analytical performance and assay performance in disease. Additionally, the review will describe the potential user benefits of adopting these new generation FLC assays, which are designed to overcome the established limitations of existing polyclonal antibody based FLC assays.

show abstract

Section: Assay Performance In Diseasementioning

confidence: 99%

Measurement of free light chains with assays based on monoclonal antibodies

Velthuis

Drayson

Campbell

2016

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…40 Recommending mass spectrometry for screening did not seem practical to the EP at this time; it will be important to keep a keen watch on technology to see if mass spectrometry becomes practical for routine laboratory studies. The evidence for this statement comprises 5 studies 30,31,[41][42][43] that evaluated the diagnostic test characteristics of SPEP and sFLC in the initial detection of M proteins. This included a high-quality systematic review, 41 an intermediate-quality diagnostic accuracy study, 42 1 low-quality diagnostic accuracy study, 31 and 2 very-low-quality diagnostic accuracy studies.…”

Section: Guideline Statementsmentioning

confidence: 99%

“…The evidence for this statement comprises 5 studies 30,31,[41][42][43] that evaluated the diagnostic test characteristics of SPEP and sFLC in the initial detection of M proteins. This included a high-quality systematic review, 41 an intermediate-quality diagnostic accuracy study, 42 1 low-quality diagnostic accuracy study, 31 and 2 very-low-quality diagnostic accuracy studies. 30,43 The aggregate risk of bias across all 5 studies was serious, but the evidence was not further downgraded for any domain.…”

Section: Guideline Statementsmentioning

confidence: 99%

Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies

Keren

Bocsi

Billman

et al. 2021

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.— The process for identifying patients with monoclonal gammopathies is complex. Initial detection of a monoclonal immunoglobulin protein (M protein) in the serum or urine often requires compilation of analytical data from several areas of the laboratory. The detection of M proteins depends on adequacy of the sample provided, available clinical information, and the laboratory tests used. Objective.— To develop an evidence-based guideline for the initial laboratory detection of M proteins. Design.— To develop evidence-based recommendations, the College of American Pathologists convened a panel of experts in the diagnosis and treatment of monoclonal gammopathies and the laboratory procedures used for the initial detection of M proteins. The panel conducted a systematic literature review to address key questions. Using the Grading of Recommendations Assessment, Development, and Evaluation approach, recommendations were created based on the available evidence, strength of that evidence, and key judgements as defined in the Grading of Recommendations Assessment, Development, and Evaluation Evidence to Decision framework. Results.— Nine guideline statements were established to optimize sample selection and testing for the initial detection and quantitative measurement of M proteins used to diagnose monoclonal gammopathies. Conclusions.— This guideline was constructed to harmonize and strengthen the initial detection of an M protein in patients displaying symptoms or laboratory features of a monoclonal gammopathy. It endorses more comprehensive initial testing when there is suspicion of amyloid light chain amyloidosis or neuropathies, such as POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes) syndrome, associated with an M protein.

show abstract

“…Nilai rujukan yang diperoleh pada penelitian ini mendekati yang diperoleh Bakker 14 di Belanda. Kajian tersebut memiliki kesamaan dengan penelitian ini, yaitu menggunakan alat dari perusahaan yang sama, Roche Diagnostic, dan metode imunoturbidimetri yang sama.…”

Section: Metodeunclassified

Nilai Rujukan Free Light Chain Serum Dengan Imunoturbidimetri

Utami¹,

Wirawan²,

Harahap³

et al. 2018

Indonesian J. Clin. Pathol. Med. Lab.

View full text Add to dashboard Cite

The light chains of immunoglobulin are produced in larger quantity rather than heavy chains, therefore small amount of free lightchains (FLC) can be found in the blood of healthy individuals. Free light chain production is increased in the clone’s proliferation ofmalignant B cells, i.e. in myeloma. Therefore the FLC level measurement can be used for diagnosis aid of myeloma and related B cellsdisorders. The aim of this study is to establish reference range of serum FLC κ, FLC λ, and κ/λ ratio in population ≥40 year’s old usingimmunoturbidimetry assay. Serum FLC κ, FLC λ and κ/λ ratio were measured in 240 healthy male and female attending medical checkup in MMC hospital. Healthy subjects were determined by anamnesis and physical examination, with routine haematology, ESR, andserum creatinine level within normal ranges. The serum FLC assays were performed in the Clinical Pathology Laboratory, RSCM, usingHitachi 912 with immunoturbidimetry method. The results were analyzed by SPSS 11.5 program. Serum FLC normal reference valuein 40-84 years old healthy subjects are: FLC κ 11.7–30.6 mg/L, FLC λ 9.7–25.0 mg/L, and κ/λ ratio 0.79–1.75. This research is thefirst study for finding serum FLC values in the Indonesian population. The normal reference value found is similar with another studyusing the same platform analyzer.

show abstract

Quantitation of Serum Free Light Chains

Cited by 4 publications

References 5 publications

Measurement of free light chains with assays based on monoclonal antibodies

Measurement of free light chains with assays based on monoclonal antibodies

Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies

Nilai Rujukan Free Light Chain Serum Dengan Imunoturbidimetri

Contact Info

Product

Resources

About